Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sorrento to Acquire SmartPharm | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sorrento to Acquire SmartPharm

Gains non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases.

By: Contract Pharma

Contract Pharma Staff

Sorrento Therapeutics, Inc. and SmartPharm Therapeutics, Inc. signed a letter of intent for Sorrento to acquire SmartPharm, a gene-encoded therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases, with broad potential for application in enhancing antibody-centric therapeutics. The transaction is expected to close in August 2020. Financial terms were not disclosed.

The companies previously entered a R&D collaboration to encode and express in vivo Sorrento’s SARS-CoV-2 neutralizing monoclonal antibodies utilizing SmartPharm’s Gene Mab plasmid nanoparticle platform.

Sorrento plans to accelerate the development of multiple candidates for in vivo gene-encoded expression of Sorrento’s antibodies, starting with Sorrento’s STI-1499, or COVI-GUARD, which is currently moving through preclinical and manufacturing requirements with an IND submission planned for August 2020. The initial clinical trial for STI-1499 is expected to be in ICU patients to evaluate safety and a preliminary look at efficacy. In vitro results have demonstrated STI-1499’s ability to completely neutralize SARS-CoV-2 infection at low doses, making STI-1499 Sorrento’s lead candidate for potential cost-effective passive protection against COVID-19.

SmartPharm’s Gene Mab platform delivers to muscles a novel low-immunogenic DNA plasmid encoded with a therapeutic antibody for long-lasting expression in vivo. If clinical trials are successful, a single administration of STI-1499dpi could allow the recipient’s own muscle cells to produce the antibody for a prolonged period of time after a single injection, potentially providing an alternative to vaccines. Manufacturing of DNA plasmids can be done with Sorrento’s in-house cGMP capabilities for a fraction of the cost associated with traditional antibody manufacturing, according to the company.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics